|
1. |
Comments From the Editor-in-Chief |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 1-2
Robert Arceci,
Preview
|
|
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
2. |
Diagnosis, Disclosure, and Informed Consent: Learning From Parents of Children With Cancer |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 3-12
Rachel Levi,
Rebecca Marsick,
Dennis Drotar,
Eric Kodish,
Preview
|
|
摘要:
Purpose:The aim of this study was to learn about and to describe retrospective perceptions of parents of the circumstances of their child's cancer diagnosis and of the informed consent process.Methods:Professional moderators conducted three focus groups with 22 parents of children with cancer who were eligible for enrollment in a Children's Cancer Group clinical trial research protocol. Each focus group consisted of seven to nine parents and was audiotaped and transcribed.Results:Parents' descriptions of the early phase of their child's illness yielded the following themes: dialogues regarding the diagnosis and treatment options occurred amidst tremendous stress; a sense of constraint and lack of control were common; parents experienced variable degrees of choice regarding their child's participation in a clinical trial; and parents provided suggestions about how to improve the informed consent process. Overall, parents did not verbalize distinctions between their understanding of their child's medical treatment, research participation, and other aspects of their child's cancer experience.Conclusions:Based on these results, the authors conclude with practical recommendations for health care professionals caring for children with cancer and call for future research about parents' understanding of treatment options, the nature of clinical trials, and experience with the diagnostic and early treatment phase of childhood cancer with larger samples of parents from multiple sites.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
3. |
Immune Reconstitution After Autologous Purged Bone Marrow Transplantation in Children |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 13-19
Naynesh Kamani,
Antonis Kattamis,
Aaron Carroll,
Donald Campbell,
Nancy Bunin,
Preview
|
|
摘要:
Purpose:Immune reconstitution was studied in 30 children who had received purged autologous bone marrow transplantation for neuroblastoma or acute myeloid leukemia (AML).Methods:Patients with neuroblastoma received high-dose chemotherapy and total body irradiation, and patients with AML received chemotherapy alone. Marrows were purged ex vivo with either antineuroblastoma monoclonal antibodies (neuroblastoma) or 4-hydroperoxycyclophosphamide (AML). Lymphocyte subsets, mitogen stimulation studies, and immunoglobulin levels were studied every 4 months.Results:There were no significant differences between the two groups of patients in lymphocyte number or subsets over time. In both groups, CD2+ and CD4+ cells were below normal in 33% of patients at 12 months. CD4+/CD8+ ratios were below normal for up to 8 months after transplantation and natural killer cells were elevated for up to 2 years in most patients. Median IgG and IgA levels were below the age mean even at 2 years after transplantation, although patients with AML had significantly higher IgG levels at 12 months compared with those with neuroblastoma. Lymphocyte proliferative responses to mitogens were markedly reduced at 4 months but returned to normal at 8 months. Despite the delay in immune reconstitution, there were no life-threatening infections.Conclusions:There appeared to be little difference in the overall kinetics of immune reconstitution between the children with neuroblastoma, who received total body irradiation and high-dose chemotherapy, and those with AML, who received high-dose chemotherapy alone as their pretransplant preparative regimen.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
4. |
A New Sensitive and Specific Combination of CD81/CD56/CD45 Monoclonal Antibodies for Detecting Circulating Neuroblastoma Cells in Peripheral Blood Using Flow Cytometry |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 20-26
Jun-ichi Nagai,
Yuji Ishida,
Noriko Koga,
Yukichi Tanaka,
Kei Ohnuma,
Yasunori Toyoda,
Akinori Katoh,
Yohko Hayabuchi,
Hisato Kigasawa,
Preview
|
|
摘要:
Purpose:Intensive chemoradiotherapy followed by peripheral blood stem cell transplantation has been introduced to treat children with advanced neuroblastoma (NBL). Detection of NBL cells in peripheral blood (PB) is important to prevent reinfusion of NBL cells. Several immunologic methods have been proposed for detecting NBL cells in hematologic samples. The development of a sensitive and specific combination of monoclonal antibodies (MoAbs) for detecting small numbers of NBL cells in PB using flow cytometry remains an important challenge.Methods:Twenty-one clinical samples from NBL tissues or smears containing NBL cells were examined for reactivity against CD81, CD56, and CD9 using an immunocytochemical technique. The expressions of CD81, CD56, CD9, and antihuman disialoganglioside GD2 MoAb (GD2) in five NBL cell lines were assayed by flow cytometry. For the evaluation of sensitivity, five NBL cell lines were added to normal PB and the detection level of the combination of CD81/CD56/CD45 MoAbs was compared with that of CD9/CD56/CD45 MoAbs (reported previously). One hundred thirty-three normal PB samples were examined to determine the sensitivity and specificity of this method.Results:All NBL cell lines showed strong positivity with CD81 and CD56 MoAb. However, CD9 MoAb was weakly positive against the five NBL cell lines. GD2 MoAb reacted strongly with four NBL cell lines, although almost the entire cell population of the SK-N-SH NBL line failed to bind the GD2 MoAb. In vitro experiments using NBL cell lines demonstrated that tumor cells added to normal PB cells could be detected by flow cytometry using CD81/CD56/CD45 MoAbs even at a concentration of 0.005%. Through comparative studies, the combination of CD81/CD56/CD45 MoAbs was found to be more sensitive and specific than that of CD9/CD56/CD45 MoAbs for detecting small numbers of NBL cells using the above cell lines.Conclusions:Triple-color flow cytometric analysis using CD81/CD56/CD45 MoAbs is useful for detecting NBL cells in PB. Further studies testing this approach using samples of PB with NBL contamination are needed to test this approach in patients.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
5. |
Early Testicular Biopsy in Males With Acute Lymphoblastic Leukemia: Lack of Impact on Subsequent Event-Free Survival |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 27-33
Michael Trigg,
Peter Steinherz,
Richard Chappell,
Helen Johnstone,
Paul Gaynon,
John Kersey,
Joel Cherlow,
Neil Grossman,
Harland Sather,
G. Hammond,
Preview
|
|
摘要:
Purpose:Children with acute lymphoblastic leukemia (ALL) who had bulky disease (lymphomatous features) at diagnosis had the highest rate of testicular relapse (20%) of any ALL subgroup on previous Children's Cancer Group (CCG) studies in the late 1980s. To limit curative, but sterilizing, testicular irradiation to those with testicular disease, testicular biopsies were performed to detect occult testicular disease within the first 6 months of treatment. Testicular irradiation then was provided to those with occult disease to increase disease-free survival. Identification of those with occult disease was believed to be a factor that would influence ultimate survival in such patients in that era.Patients and Methods:One hundred ninety-nine patients had bilateral testicular wedge biopsies performed during the first maintenance therapy phase of the four different chemotherapy regimens. Patients with positive biopsy results were treated with testicular irradiation and continued on therapy.Results:Eleven of 199 biopsy results (5.5%) were judged positive. Patients with positive biopsy results given testicular radiation had a 45% subsequent adverse event rate, compared with 36% for those with a negative biopsy results (P= 0.4). The survival rates for the two groups were similar. The low rate of positive biopsy specimens resulted in discontinuation of the procedure before closure of the study.Conclusion:Positive testicular biopsy results early in remission identified patients at a slightly higher risk of subsequent adverse events but did not influence survival. However, because negative biopsy results (94.5%) did not alter the prescribed treatment, the small number of positive biopsy results did not warrant undertaking the procedure in most male patients with ALL, and this procedure was abandoned.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
6. |
Extramedullary Myeloid Tumors in Children: The Limited Value of Local Treatment |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 34-40
R. Jenkin,
M. Al-Shabanah,
A. Al-Nasser,
H. El-Solh,
R. Aur,
R. Al Sudairy,
M. Mustafa,
I. Al Fawaz,
A. Gray,
Martins da Cunha,
M. Ayas,
M. Al Mahr,
A. Kofide,
A. Mahgoub,
S. Rifai,
A. Belgaumi,
A. Al Jefri,
A. Al Musa,
R. Sabbah,
Preview
|
|
摘要:
Purpose:To determine the incidence of extramedullary tumors (EMT) in Saudi Arabian children with acute myeloid leukemia, the factors associated with these tumors and the impact of local treatment on local tumor control, complete remission and survival rates.Patients and Methods:One hundred children, median age 6 years, who received their primary treatment for acute myeloid leukemia at King Faisal Specialist Hospital and Research Center, from 1983 to 1997 were studied. EMT at diagnosis occurred in 18 (18%) patients at 25 sites. Meningeal leukemia, hepatosplenomegaly, lymph node enlargement, gingival hypertrophy, and cutaneous infiltration were not included in the definition of EMT. With these exclusions, children with EMT were younger than those without EMT (median age, 3.5v7.5 years) and were more likely to have meningeal leukemia at diagnosis (33%v10%). The t(8;21) translocation was associated with a 47% EMT incidence compared with 23% without the translocation. Local radiation treatment was given to 16 of 25 (64%) EMT sites.Results:The overall 5-year survival rate for all patients was 28%, and this was not significantly influenced by the drug regimen used, meningeal leukemia at diagnosis, the presence of the (8;21) translocation, M4 and M5 morphology combined, or EMT at diagnosis. Significant differences were observed in the 5-year survival rates for patients who underwent allogeneic bone marrow transplantation (52%; N = 37) and those who attained complete remission (CR) but did not undergo transplantation (21%; N = 44) and those who did not achieve complete remission with initial therapy (5%; N = 19). Systemic and local EMT CR was achieved in 17 of 18 patients with EMT, including 12 patients who underwent radiation treatment and 5 of 6 of those who did not. Isolated relapse was not seen at an EMT site and was not noted at any later stage of the disease.Conclusions:Permanent local control at sites of EMT was achieved in all patients who attained a bone marrow CR, whether or not the site was irradiated. Local radiation treatment of an EMT site did not appear to contribute to overall CR and survival rates. The use of radiation treatment should be conservative and limited to patients in whom there is a real and immediate threat to vision or renal function or when the spinal cord is compromised.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
7. |
Announcement |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 40-40
Preview
|
|
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
8. |
Oral Methotrexate for Recurrent Brain Tumors in Children: A Pediatric Oncology Group Study |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 41-44
Arlynn,
Mulne Jonathan,
Ducore Roy,
Elterman Henry,
Friedman Jeffrey,
Krischer Larry,
Kun Jonathan,
Shuster Richard,
Preview
|
|
摘要:
Purpose:Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied.Methods:Eight dosages of MTX 7.5 mg/m2every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued.Results:The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable.Conclusion:Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
9. |
Increased Expression of Lung Resistance-Related Protein and Multidrug Resistance-Associated Protein Messenger RNA in Childhood Acute Lymphoblastic Leukemia |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 45-49
Besim,
Ogretmen Julio,
Barredo Ahmad,
Preview
|
|
摘要:
Immunophenotype might be an important indicator for multidrug resistance (MDR) profiles in childhood acute lymphoblastic leukemia (ALL). The authors analyzed the messenger RNA (mRNA) levels of MDR1, multidrug resistance-associated protein (MRP), and lung resistance-related protein (LRP) by reverse transcriptase-polymerase chain reaction (RT-PCR) in childhood pre-B ALL, T-cell ALL, and acute nonlymphoblastic leukemia (ANLL). Results showed that MRP and LRP, but not MDR1, mRNAs are overexpressed, particularly in children with pre-B ALL compared with T-cell ALL and ANLL tested. In addition, the MRP and LRP mRNA expression levels in initial diagnosis and first relapse samples of one patient with pre-B ALL were similar. Consequently, these preliminary results suggest that the expression of these MDR-related genes in childhood ALL might be regulated differently in a lineage dependent manner.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
10. |
Treatment of Iron Deficiency Anemia and Associated Protein-Losing Enteropathy in Children |
|
Journal of Pediatric Hematology/Oncology,
Volume 22,
Issue 1,
2000,
Page 50-54
H.,
Nickerson Teresa,
Silberman Roger,
Park Edna,
DeVries Steven,
Preview
|
|
摘要:
Purpose:The aims of this study were to evaluate the response of oral iron treatment in children with iron deficiency anemia (IDA) fed whole cow's milk (WCM) or soy formula; to compare the incidence of fecal blood loss in infants fed WCM and soy formula; and to evaluate the incidence and relation of protein-losing enteropathy (PLE) and IDA by testing serum albumin, fecal blood loss, and fecal α1-antitrypsin (α1AT).Methods:Twenty-four children with nutritional IDA were randomly assigned to receive either 16 oz WCM or soy formula daily. Both groups were treated with daily therapeutic oral iron during 12 weeks. Stool specimens for hemoglobin losses were collected at weeks 0, 3, 6, and 12. Levels of serum albumin and fecal α1AT were tested at diagnosis and when IDA was corrected.Results:Anemia was corrected in 21 of the 24 children by week 6 or 12. Median fecal hemoglobin losses were not increased in either group at diagnosis or during treatment. Seven of 24 children had PLE at diagnosis with elevated fecal α1AT levels of 72 to 381 mg/dL that returned to normal after correction of IDA. Their initial fecal α1AT levels averaged 170 mg/dL at diagnosis and 21 mg/dL after the IDA was corrected. Excessive WCM intake of 30 oz/day or more was present in 63% of the infants.Conclusions:Treatment of nutritional IDA with oral iron was just as effective with a limited quantity of either WCM or soy formula. Fecal hemoglobin losses were uncommon and did not differ in children at diagnosis or during treatment of IDA. PLE associated with IDA resolves when the IDA is corrected, but differences between children fed WCM or soy formula could not be detected.
ISSN:1077-4114
出版商:OVID
年代:2000
数据来源: OVID
|
|